What is InsiderStreet.ai?

InsiderStreet.ai is a free financial intelligence platform tracking smart-money signals — insider trades, congressional stock disclosures, hedge fund positions, ETF flows, dark pool activity, and short interest — across 88,000+ securities.

How do I track which hedge funds own a stock?

On any stock page on InsiderStreet, the Hedge Fund Holders tab shows every fund holding that stock — names, position size, quarterly changes, and fund flows. Data is sourced from SEC institutional ownership disclosures.

How do I see which Congress members trade a stock?

Each stock page has a Smart Money tab that shows congressional disclosures under the STOCK Act — senators and representatives, transaction type, date, and dollar range — typically disclosed within 45 days of the trade.

SOLV

NYSE · USD

Solventum Corporation

Healthcare · Medical - Instruments & Supplies

CEO Bryan C. Hanson Employees 10,000 R&D / revenue 8.9%

Live stock page Read the factsheet

Last price

$85.81−2.33%last session

Market cap

$14.6B

P/E (TTM)

10.4x

From 52w high

−8.9%

From 52w low

+37.6%

1-year return

+20.1%

RSI 14 · vs SMA200

42.4 · +9.6%

IS score

37.3/ 100

Factor model across 8 sub-scores, ranked against 3,010 US stocks. Describes the business, not the outlook.

Download full factsheet (PDF)

One year, rebased to 100

SOLV SPY XLV (sector ETF) · weekly closes

Score DNA

Each bar is a 0-100 score within the scored universe

Profitability

Growth

Value

Momentum

Risk (safety)

Quality

Balance sheet

Earnings quality

Flags

Strengths

✓ Congress buying

Warnings

▲ Negative free cash flow

Observations

Moat model: Weak, Cost AdvantagePiotroski 7 / 9Altman Z 2.1Beta 0.692 of 4 smart-money sources active

Smart-money strip

Each disclosure source on its own window. Filings coinciding is not coordination.

INSForm 4 · 180 days

Insider open-market buys

No open-market sales on file

No Form 144 notices in 12 months

CONGSTOCK Act · 180 days

Congressional purchases

Last disclosed purchase 2026-05-01

Members disclose in ranges, 30-45 days after the trade

13F13F · quarter to 2026-06-30

Net change in institutional holders

122 new holders, 110 closed

885 filers hold 74.4% · 251 added, 286 trimmed

ETFETF holdings · 30 days

Net funds accumulating

−8

462 funds adding shares

470 funds trimming · counts of funds, not dollars

DARKFINRA · daily

Short-sale share of off-exchange volume

41.9%

20-day avg 52.1%, 50-day avg 52.9%

Latest 10.2 pp under its 20-day average · a flow, not short interest

Key financials · FY2025

USD, fiscal year. Stock-based compensation is non-cash; shown against FCF.

Income statement

Revenue$8.3B

Revenue growth YoY+0.9%

Gross margin53.5%

Operating income$2.2B

Operating margin26.2%

Net income$1.6B

Net margin18.7%

EPS (diluted)$8.88

Cash flow

Operating cash flow$369.0M

Capital expenditure$379.0M

Free cash flow−$10.0M

FCF conversion (FCF / OCF)-2.7%

Stock-based compensation$161.0M

FCF less SBC−$171.0M

Buybacks$0

Dividends$0

Balance sheet & returns

Cash & short-term investments$878.0M

Total debt$5.0B

Net debt$4.2B

Shareholders' equity$5.0B

Goodwill & intangibles$8.3B

Debt / equity1.10

ROE (TTM)29.0%

ROIC (TTM)15.9%

Operating margin by fiscal year

Revenue $8.2B (FY2021) to $8.3B (FY2025), a 0.5% CAGR.

Valuation

P/E (TTM)10.4x

EV / EBITDA7.9x

Price / sales1.76x

Price / FCFn/m

FCF yield-0.81%

Buyback yield0.00%

SBC / revenue2.0%

Price / book3.10x

Forward P/E FY202612.0x

Forward P/E FY202711.7x

Forward P/E FY202810.6x

Forward multiples divide today's price by Street EPS estimates. Street mean target $101.00 across 6 analysts last quarter is theirs, not ours.

SOLV vs industry median

111 companies in Medical - Instruments & Supplies

SOLV (TTM)Industry median Asset turnover 0.58 vs industry 0.60 · financial leverage 2.97

Earnings delivery

Next report 2026-11-05 · consensus EPS $1.35

100%

beat rate, 10 of 10 quarters

+10.2%

median EPS surprise

longest beat streak

EPS surprise in % vs the consensus at the time, oldest (left) to newest, 2024-05-09 to 2026-08-05. Bars cap at ±60%.

Peers

Market-cap band, not the industry cohort above

Company	Mkt cap	P/E	ROE	Net margin	Rev growth	12m return
SOLV Solventum Corporation	$14.6B	10.4x	29.0%	17.3%	+0.9%	+20.1%
BAX Baxter International Inc.	$13.1B	n/m	-15.7%	4.3%	+5.4%	+10.3%
HOLX Hologic, Inc.	$17.0B	30.3x	10.9%	17.1%	+2.2%	+19.1%
RGEN Repligen Corporation	$11.1B	237.1x	2.0%	2.5%	+16.5%	+13.5%
AVTR Avantor, Inc.	$11.1B	n/m	-9.7%	2.3%	−1.6%	+12.7%
COO The Cooper Companies, Inc.	$11.0B	19.8x	6.8%	40.6%	+4.7%	—
ATR AptarGroup, Inc.	$7.9B	22.2x	13.6%	8.5%	+8.9%	—
WST West Pharmaceutical Services	$27.0B	48.8x	19.1%	17.7%	+12.4%	—

12-month window: SPY +15.9%, sector ETF XLV +24.2%. Past returns describe history only.

Recent 8-K filings

2026-08-05Earnings Release; Exhibits

2026-08-05Regulation FD; Other Events; Exhibits

2026-07-20Officer/Director Change

2026-06-05Other Events; Exhibits

2026-05-27Officer/Director Change; Exhibits

2026-05-20Shareholder Vote

Context

Shares outstanding170,223,735

Free float84.9%

Institutional ownership74.4%

Beta0.69

Dividend yield0.00%

Last dividendNone on file

50 / 200-day average$88.37 / $78.23

Large-cap Healthcare median P/E29.7x

Full factsheet

The PDF carries everything on this page plus the cash-allocation waterfall, Form 144 notices, 13F holder detail, dark-pool and short-flow history, seasonality and the moat assessment (Weak).

Read it in the browser Download (PDF)

All fundamentals · 140 measures in 13 categories

Percentile = where SOLV sits among 26 scored companies in Medical - Instruments & Supplies (0 = lowest value, 100 = highest). It is a position, not a grade.

Valuation Profitability (TTM)Returns on capital Growth Margin history & stability Liquidity (latest quarter)Leverage & solvency (latest quarter)Efficiency Cash flow & earnings quality Dividends & buybacks Scores & forensic checks Per share Size (TTM)

Valuation

Measure	SOLV	Industry median	Industry percentile	Sector median
P/E (TTM)	10.2x	43.3x	7th	27.6x
PEG (P/E ÷ 3-yr EPS CAGR)	—
Price / sales	1.8x	2.4x	33rd	3.7x
Price / book	3.0x	2.9x	58th	3.6x
Price / tangible book	—
Price / free cash flow	—
Price / operating cash flow	69.9x	18.6x	91st	17.1x
Enterprise value	$19.5B	$6.9B	76th	$2.5B
EV / sales	2.3x	2.7x	46th	3.8x
EV / EBITDA	7.1x	20.4x	5th	16.2x
EV / EBIT	9.9x	32.2x	6th	23.0x
EV / free cash flow	—
Earnings yield	9.8%	0.6%	96th	-0.3%
FCF yield	-0.8%	3.8%	8th	1.7%
Operating cash flow yield	1.4%	4.9%	20th	2.9%
Graham number (per share)	$71.36	$48.19	64th	$26.70

Profitability (TTM)

Measure	SOLV	Industry median	Industry percentile	Sector median
Gross margin	54.7%	53.8%	56th	65.1%
EBITDA margin	32.9%	13.9%	88th	6.6%
Operating margin	25.0%	9.8%	88th	3.5%
EBIT margin	23.6%	6.8%	88th	2.4%
Net margin	17.3%	1.9%	88th	0.3%
NOPAT margin	21.1%	6.6%	88th	2.7%
FCF margin	-1.4%	7.9%	8th	4.3%
Operating cash flow margin	2.5%	11.4%	12th	7.1%
R&D / revenue	8.7%	5.9%	75th	12.4%
SG&A / revenue	39.6%	36.9%	58th	37.9%
Stock comp / revenue	1.5%	1.7%	48th	4.5%
Effective tax rate	15.4%	21.0%	8th	21.0%

Returns on capital

Measure	SOLV	Industry median	Industry percentile	Sector median
ROE (on average equity)	34.0%	2.0%	100th	0.8%
ROA	9.8%	1.2%	84th	-0.3%
ROIC	18.1%	3.8%	76th	5.5%
ROCE	18.5%	3.9%	84th	2.3%
Return on tangible assets	13.4%	3.3%	80th	1.7%
Cash ROIC (OCF / invested capital)	2.2%	8.3%	12th	9.7%
Gross profitability (GP / assets)	31.9%	24.9%	68th	29.9%
ROIC, 3-yr average	7.3%	2.1%	76th	2.6%
ROIC, 5-yr average	—
ROE, 5-yr average	—
Incremental ROIC	-104.5%	34.6%	12th	17.2%

Growth

Measure	SOLV	Industry median	Industry percentile	Sector median
Revenue growth (TTM YoY)	-0.9%	8.8%	22nd	10.5%
Revenue growth (QoQ)	10.1%	4.8%	88th	7.2%
Revenue CAGR, 3 yr	—
Revenue CAGR, 5 yr	—
Gross profit CAGR, 3 yr	—
Operating income CAGR, 3 yr	—
Net income growth (TTM YoY)	277.4%	20.4%	100th	17.5%
Net income CAGR, 3 yr	—
EPS growth (TTM YoY)	279.1%	22.3%	100th	19.2%
EPS CAGR, 3 yr	—
EPS CAGR, 5 yr	—
FCF growth (TTM YoY)	—
FCF CAGR, 3 yr	—
Operating cash flow CAGR, 3 yr	—
Book value CAGR, 3 yr	—
Dividend CAGR, 3 yr	—
Sustainable growth rate	34.0%	6.8%	100th	12.2%

Margin history & stability

Measure	SOLV	Industry median	Industry percentile	Sector median
Gross margin, 3-yr average	54.6%	54.6%	50th	62.6%
Operating margin, 3-yr average	15.3%	7.2%	73rd	1.0%
Net margin, 3-yr average	8.7%	2.3%	68th	-2.6%
FCF margin, 3-yr average	4.9%	8.8%	23rd	3.2%
Revenue stability (0-1)	0.74	0.73	52nd	0.80
Earnings stability (0-1)	0.90	0.40	91st	0.37
Margin stability (0-1)	1.00	0.96	100th	0.93

Liquidity (latest quarter)

Measure	SOLV	Industry median	Industry percentile	Sector median
Cash & short-term investments	$403.0M	$316.3M	64th	$330.9M
Net cash (− = net debt)	−$4.9B	−$416.9M	12th	$8.4M
Working capital	$78.0M	$705.4M	8th	$381.1M
Current ratio	1.02	2.54	4th	3.02
Quick ratio	0.74	2.12	8th	2.51
Cash ratio (cash + ST investments / current liabilities)	0.11	0.83	8th	1.43
Defensive interval (days)	271 days	399 days	40th	415 days

Leverage & solvency (latest quarter)

Measure	SOLV	Industry median	Industry percentile	Sector median
Total debt	$5.3B	$1.0B	88th	$289.1M
Debt / equity	1.10	0.49	88th	0.45
Net debt / equity	1.02	0.22	88th	−0.13
Debt / assets	37.1%	28.5%	80th	24.4%
Debt / capital	52.4%	32.8%	88th	31.1%
Debt / EBITDA	1.94	3.77	30th	2.62
Net debt / EBITDA	1.79	1.79	50th	1.42
Interest coverage (EBIT / interest)	7.4x	2.3x	76th	2.1x
Cash interest coverage	0.8x	5.3x	5th	3.6x
Debt payback (years of OCF)	25.3 yrs	5.1 yrs	100th	2.7 yrs
Liabilities / assets	66.3%	43.2%	84th	49.8%
IS credit model rating	BBB-	—		—
Implied credit spread (bps)	350	288	52nd	225

Efficiency

Measure	SOLV	Industry median	Industry percentile	Sector median
Asset turnover	0.57	0.55	56th	0.56
Fixed asset turnover	5.31	3.55	76th	4.87
Inventory turnover	3.8	2.7	68th	2.7
Receivables turnover	7.0	6.3	60th	6.4
Days sales outstanding	52 days	58 days	40th	57 days
Days inventory outstanding	97 days	138 days	32nd	136 days
Days payables outstanding	65 days	55 days	68th	59 days
Cash conversion cycle (days)	84 days	124 days	24th	70 days
Capex / revenue	3.9%	3.9%	50th	2.6%
Capex / depreciation	0.43	0.48	42nd	0.55
Operating expense ratio	50.0%	43.1%	75th	56.5%

Cash flow & earnings quality

Measure	SOLV	Industry median	Industry percentile	Sector median
Operating cash flow / net income	0.15	1.97	7th	1.61
FCF / net income	−0.08	1.64	7th	1.36
FCF / operating cash flow	-56.5%	74.0%	0th	81.2%
Capex / operating cash flow	156.5%	26.0%	100th	18.8%
Accruals ratio	8.4%	-5.1%	100th	-5.4%
Sloan accruals ratio	-8.7%	-2.4%	12th	-1.3%
Earnings quality score (0-1)	0.25	1.00	0th	0.75

Dividends & buybacks

Measure	SOLV	Industry median	Industry percentile	Sector median
Dividend yield	0.0%	0.0%	0th	0.0%
Dividend per share (TTM)	$0.00	$0.00	0th	$0.00
Payout ratio (dividends / net income)	0.0%	0.0%	0th	0.0%
Dividends / FCF	—
Dividend growth (YoY)	—
Buyback yield	2.4%	0.5%	76th	0.0%
Shareholder yield (dividends + buybacks)	2.4%	0.7%	68th	0.0%
Share count change (YoY)	-0.5%	0.0%	46th	2.0%
Buybacks, last 5 years	$0	$56.9M	0th	$0

Scores & forensic checks

Measure	SOLV	Industry median	Industry percentile	Sector median
IS score	37	43	28th	46
IS profitability	55	32	80th	22
IS growth	59	57	52nd	60
IS value	67	42	100th	39
IS momentum	49	70	26th	67
IS risk (safety)	50	80	16th	80
IS quality	52	58	44th	49
IS balance sheet	49	53	44th	55
IS earnings quality	35	60	16th	56
IS cash flow	3	51	0th	41
Piotroski F-score (0-9)	7	6	68th	5
Altman Z-score	2.1	3.2	32nd	3.2
Beneish M-score	−2.08	−2.68	91st	−2.62
Ohlson O-score	−7.35	−8.33	64th	−7.16
IS credit score	51	58	44th	62

Per share

Measure	SOLV	Industry median	Industry percentile	Sector median
EPS, diluted (TTM)	$8.22	$0.50	92nd	−$0.03
Book value per share	$27.52	$18.30	56th	$7.10
Tangible book per share	−$18.64	$3.11	8th	$1.91
Revenue per share	$47.65	$17.79	84th	$9.38
FCF per share	−$0.68	$1.57	8th	$0.46
Operating cash flow per share	$1.20	$2.10	28th	$0.93
Cash per share	$2.31	$3.47	28th	$3.51

Size (TTM)

Measure	SOLV	Industry median	Industry percentile	Sector median
Market cap	$14.6B	$5.4B	80th	$2.4B
Revenue	$8.3B	$2.7B	84th	$770.2M
EBITDA	$2.7B	$262.0M	92nd	$56.1M
Net income	$1.4B	$35.8M	92nd	−$3.3M
Free cash flow	−$118.0M	$158.7M	4th	$41.2M
Total assets	$14.2B	$4.6B	84th	$1.3B
Shareholders' equity	$4.8B	$2.4B	68th	$568.4M
Employees	20,584	11,685	88th	1,086

Insider transactions, last 6 months

Form 4 · most recent 12

Date	Insider	Type	Shares	Price	Value	Owned after
2026-09-01	Hanson Bryan C Director, Chief Executive Officer	Option exercise	67,261	—	—	211,983
2026-09-01	Hanson Bryan C Director, Chief Executive Officer	Tax withholding	26,468	$90.95	$2.4M	185,515
2026-09-01	Hanson Bryan C Director, Chief Executive Officer	Option exercise	67,261	—	—	0
2026-08-17	Zieselman Neil Craig SVP, Controller & CAO	Award / grant	6,911	—	—	6,911
2026-05-15	Alban Carlos Director	Award / grant	3,300	—	—	3,300
2026-05-15	Cox Carrie Smith Director	Award / grant	4,848	—	—	4,848
2026-05-15	Devore Susan D. Director	Award / grant	3,300	—	—	3,300
2026-05-15	Edwards Shirley Ann Director	Award / grant	3,300	—	—	3,300
2026-05-15	Eisenberg Glenn A Director	Award / grant	3,300	—	—	3,300
2026-05-15	Harris Bernard A Jr Director	Award / grant	3,300	—	—	3,300
2026-05-15	May Karen J Director	Award / grant	3,300	—	—	3,300
2026-05-15	Mily Elizabeth Director	Award / grant	3,300	—	—	3,300

Shares acquired vs disposed, by month

acquired disposed · all Form 4 types

By transaction type, 6 months

Type	Direction	Filings	Shares	Value
Award / grant	Acquired	12	44,759	—
Option exercise	Acquired	19	169,231	—
Option exercise	Disposed	19	169,231	—
Tax withholding	Disposed	8	52,418	$4.3M
—	Disposed	1	0	—

Awards, option exercises and tax withholding are compensation mechanics; open-market buys and sales are the discretionary ones.

Form 144 notices

Filed	Filer	Shares proposed	Est. proceeds
None on file.

A Form 144 is notice of a proposed sale, not a confirmed one.

Congress trades

12 months: House 4 trades (1 purchases) · Senate 1 (1 purchases)

Traded	Member	Chamber	Type	Amount	Disclosed
2026-05-01	Ro Khanna	House	Purchase	$1,001 - $15,000	2026-06-11
2026-03-27	Alan Armstrong	Senate	Purchase	$1,001 - $15,000	2026-07-21
2025-12-31	James French Hill	House	Sale	$15,001 - $50,000	2026-01-26
2025-12-31	French Hill	House	Sale (Full)	$15,001 - $50,000	2026-01-23
2025-12-30	French Hill	House	Sale (Full)	$15,001 - $50,000	2026-01-23
2025-02-06	Ron Wyden	Senate	Sale (Full)	$1,001 - $15,000	2025-02-21
2025-02-06	Ron Wyden	Senate	Sale (Full)	$1,001 - $15,000	2025-02-20
2025-02-06	Ronald Lee Wyden	Senate	Sale (Full)	$1,001 - $15,000	2025-02-20

STOCK Act disclosures, in ranges, filed up to 45 days after the trade.

Largest 13F holders

Quarter to 2026-06-30, the latest most managers have filed

Manager	Shares	Value	% of shares out
Independent Franchise Partners LLP	16,170,038	$1.2B	9.50%
BlackRock, Inc.	9,761,863	$753.1M	5.73%
VANGUARD CAPITAL MANAGEMENT LLC	9,624,829	$742.6M	5.65%
TRIAN FUND MANAGEMENT, L.P.	8,236,753	$635.5M	4.84%
VANGUARD PORTFOLIO MANAGEMENT LLC	6,328,641	$488.3M	3.72%
DAVIS SELECTED ADVISERS	6,307,729	$486.7M	3.71%
STATE STREET CORP	5,639,230	$435.1M	3.31%
GEODE CAPITAL MANAGEMENT, LLC	4,910,624	$378.3M	2.88%
Invesco Ltd.	3,309,915	$255.4M	1.94%
FMR LLC	2,079,141	$160.4M	1.22%
STATE FARM MUTUAL AUTOMOBILE INSURANCE CO	2,069,279	$159.6M	1.22%
Diamond Hill Capital Management, LLC	1,945,121	$150.1M	1.14%
DIMENSIONAL FUND ADVISORS LP	1,817,658	$140.2M	1.07%
Madison Avenue Partners, LP	1,741,221	$134.3M	1.02%
NORGES BANK	1,713,676	$132.2M	1.01%

Institutional ownership by quarter

% of shares held by 13F filers

Number of 13F filers holding

Holder changes by quarter

Quarter	Holders	Ownership	New	Increased	Reduced	Closed
2026-06-30	885	74.4%	122	251	286	110
2026-03-31	881	74.2%	84	274	278	126
2025-12-31	938	72.7%	152	257	308	63
2025-09-30	863	70.2%	79	259	266	84
2025-06-30	883	66.3%	75	227	352	89
2025-03-31	908	66.0%	92	218	365	98
2024-12-31	933	63.4%	140	204	392	111
2024-09-30	924	62.0%	144	175	429	103
2024-06-30	895	60.8%	850	25	12	18
2024-03-31	63	1.3%	63	0	0	0

Schedule 13D / 13G filers

Filed	Form	Filer	% of class	Shares
2026-03-27	SCHEDULE 13G/A	The Vanguard Group	0.0%	0
2026-01-27	SCHEDULE 13G/A	Independent Franchise Partners, LLP	8.8%	15,355,691
2025-11-13	SCHEDULE 13G/A	Independent Franchise Partners, LLP	7.4%	12,899,240
2025-08-18	SCHEDULE 13G/A	3M Company	14.8%	25,569,190

Required above 5% of a class; 13G is the passive form.

ETFs with the largest holding

ETF	Weight in fund	Holding value
VITSX	0.02%	$404.4M
VTSAX	0.02%	$404.4M
VSMPX	0.02%	$404.4M
VTI	0.02%	$404.4M
VFIAX	0.02%	$334.8M
VFFSX	0.02%	$334.8M

Share structure

Shares outstanding170,223,735

Float144,580,197

Free float84.9%

Income statement

Fiscal years, USD

	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$8.2B	$8.1B	$8.2B	$8.3B	$8.3B
Cost of revenue	$3.2B	$3.4B	$3.5B	$3.7B	$3.9B
Gross profit	$4.9B	$4.7B	$4.7B	$4.6B	$4.5B
R&D	$766.0M	$767.0M	$758.0M	$775.0M	$739.0M
SG&A	$2.3B	$2.2B	$2.2B	$2.8B	$3.1B
Operating income	$1.9B	$1.7B	$1.7B	$1.0B	$2.2B
EBITDA	$2.5B	$2.3B	$2.2B	$1.5B	$2.5B
Pretax income	$1.9B	$1.7B	$1.7B	$605.0M	$1.7B
Income tax	$422.0M	$349.0M	$321.0M	$127.0M	$157.0M
Net income	$1.5B	$1.3B	$1.3B	$479.0M	$1.6B
EPS, diluted	$8.47	$7.79	$7.79	$2.76	$8.88
Diluted shares	172.5M	172.5M	172.7M	173.7M	175.3M

Balance sheet

	FY2021	FY2022	FY2023	FY2024	FY2025
Cash & short-term investments	$91.0M	$61.0M	$194.0M	$762.0M	$878.0M
Receivables	$1.2B	$1.2B	$1.3B	$1.2B	$1.0B
Inventory	$813.0M	$873.0M	$857.0M	$965.0M	$1.1B
Total current assets	$2.2B	$2.2B	$2.5B	$3.2B	$3.9B
PP&E, net	$1.3B	$1.3B	$1.5B	$1.6B	$1.3B
Goodwill & intangibles	$10.3B	$9.7B	$9.4B	$8.9B	$8.3B
Total assets	$14.1B	$13.6B	$13.9B	$14.5B	$14.3B
Accounts payable	$320.0M	$348.0M	$477.0M	$618.0M	$687.0M
Total current liabilities	$1.4B	$1.3B	$1.7B	$2.7B	$3.1B
Long-term debt	$0	$0	$8.3B	$7.8B	$5.0B
Total liabilities	$2.0B	$1.9B	$2.3B	$11.5B	$9.2B
Shareholders' equity	$12.1B	$11.7B	$11.7B	$3.0B	$5.0B

Cash flow statement

Outflows are negative

	FY2021	FY2022	FY2023	FY2024	FY2025
Net income	$1.5B	$1.3B	$1.3B	$479.0M	$1.6B
Depreciation & amortization	$597.0M	$578.0M	$561.0M	$555.0M	$489.0M
Stock-based compensation	$38.0M	$37.0M	$39.0M	$112.0M	$161.0M
Change in working capital	$67.0M	−$202.0M	$126.0M	$160.0M	−$119.0M
Operating cash flow	$2.2B	$1.7B	$1.9B	$1.2B	$369.0M
Capital expenditure	−$277.0M	−$251.0M	−$290.0M	−$380.0M	−$379.0M
Free cash flow	$1.9B	$1.4B	$1.6B	$805.0M	−$10.0M
Investing cash flow	−$278.0M	−$253.0M	−$230.0M	−$380.0M	$2.8B
Net debt issued / repaid	$0	$0	$0	$8.0B	−$3.1B
Buybacks	$0	$0	$0	$0	$0
Dividends paid	$0	$0	$0	$0	$0

Ratio history

Margins on the fiscal-year (TTM at Q4) basis; multiples at each year end

	FY2024	FY2025
Gross margin	54.8%	53.5%
Operating margin	10.5%	26.2%
Net margin	3.9%	18.7%
FCF margin	7.5%	-0.1%
ROE	8.2%	38.9%
ROIC	5.6%	21.5%
ROA	1.7%	10.8%
Debt / equity	2.71	1.00
Interest coverage	1.8x	5.9x
Current ratio	1.20	1.23
Revenue growth	—	+33.5%
EPS growth	—	+540.0%
P/E at year end	47.6x	8.9x
EV / EBITDA at year end	18.4x	6.4x
FCF yield at year end	4.03%	-0.07%
Dividend payout	0.0%	0.0%

Revenue by region · FY2025

UNITED STATES$4.7B · 56%

Non-US$3.7B · 44%

Street estimates by fiscal year

Next report 2026-11-05 · consensus EPS $1.35 · these are analysts' numbers, not ours

Fiscal year	Revenue (mean)	Revenue range	EPS (mean)	EPS range	Analysts	P/E on mean EPS
2026	$8.2B	$8.1B – $8.3B	$7.16	$7.07 – $7.49	9	12.0x
2027	$8.5B	$8.4B – $8.6B	$7.33	$6.55 – $7.71	9	11.7x
2028	$8.9B	$8.7B – $9.0B	$8.07	$4.21 – $10.67	5	10.6x

Reported vs expected, every quarter on file

Reported	EPS expected	EPS actual	EPS surprise	Revenue expected	Revenue actual	Revenue surprise
2026-08-05	$1.90	$2.55	+34.2%	$2.2B	$2.2B	+2.6%
2026-05-05	$1.35	$1.48	+9.6%	$2.0B	$2.0B	+2.0%
2026-02-26	$1.50	$1.57	+4.7%	$2.0B	$2.0B	+1.8%
2025-11-06	$1.43	$1.50	+4.9%	$2.1B	$2.1B	+2.0%
2025-08-07	$1.45	$1.69	+16.6%	$2.1B	$2.2B	+2.0%
2025-05-08	$1.21	$1.34	+10.7%	$2.0B	$2.1B	+2.7%
2025-02-27	$1.31	$1.41	+7.6%	$2.1B	$2.1B	+1.1%
2024-11-07	$1.39	$1.64	+18.0%	$2.1B	$2.1B	+1.2%
2024-08-08	$1.51	$1.56	+3.3%	$2.0B	$2.1B	+1.6%
2024-05-09	$1.75	$2.08	+18.9%	$2.0B	$2.0B	+2.5%

Off-exchange (dark pool) volume, weekly

FINRA ATS, $ billions · through the week of 2026-08-31 (FINRA publishes with a delay)

Week of	Notional	Shares	Trades
2026-08-31	$108.1M	1,176,616	37,972
2026-08-24	$127.9M	1,400,612	41,134
2026-08-17	$131.4M	1,491,975	43,683
2026-08-10	$129.9M	1,507,399	44,037
2026-08-03	$220.6M	2,579,862	56,695
2026-07-27	$235.5M	2,752,916	65,668

Short-sale share of off-exchange volume

daily 20-day average

Date	Short share	Short volume	Total volume
2026-10-15	41.9%	135,552	323,137
2026-10-14	59.3%	164,236	276,957
2026-10-13	50.6%	162,506	321,260
2026-10-12	47.3%	292,468	618,774
2026-10-09	56.8%	165,126	290,826
2026-10-08	42.5%	156,603	368,708
2026-10-07	63.9%	208,080	325,484
2026-10-06	55.5%	139,195	250,910
2026-10-05	72.9%	286,055	392,401
2026-10-02	76.4%	264,151	345,784

A daily flow measure from FINRA, not short interest.

Seasonality

Average return by calendar month

Month	Avg return	Up years	Years
None on file.

History, not a forecast.

Indicators

as of 2026-10-16

RSI 1442.4

MFI39.3

ADX16.8

Stochastic %K / %D55.8 / 51.6

Williams %R-62.0

CCI-78

TSI / signal-9.9 / -5.4

Chaikin money flow-0.06

ATR$2.17

Bollinger width5.6%

Volume vs 20-day avg0.75x

SupertrendDown

Moving averages and bands

level (price vs level)

SMA 20$87.69 (−2.1%)

SMA 50$88.43 (−3.0%)

SMA 200$78.26 (+9.6%)

EMA 21$87.48 (−1.9%)

EMA 50$86.95 (−1.3%)

EMA 200$80.50 (+6.6%)

Bollinger upper$90.16 (−4.8%)

Bollinger lower$85.23 (+0.7%)

Parabolic SAR$83.41 (+2.9%)

Open the live chart, 110+ indicators

About Solventum Corporation

Solventum Corporation, established in 2023 and headquartered in Saint Paul, Minnesota, operates as a healthcare entity dedicated to pioneering, producing, and commercializing diverse solutions that address critical needs for both customers and patients. The company's business activities are organized into four principal segments. The Medsurg division furnishes various products and services, including sophisticated wound care items, intravenous (I.V.) site management tools, sterilization assurance systems, temperature regulation devices, surgical instruments, stethoscopes, and medical electrodes. Its Dental Solutions segment provides a comprehensive range of dental and orthodontic offerings, such as brackets, clear aligners, restorative filling materials, and bonding agents. The Health Information Systems division concentrates on advanced software platforms, covering functionalities like computer-assisted physician documentation, direct billing and coding automation, classification frameworks, voice recognition capabilities, and data visualization tools. Finally, the Purification and Filtration segment supplies an array of purification and filtration technologies, including various filters, purifiers, cartridges, and specialized membranes.

https://www.solventum.com

Key executives

Name	Title	Pay	Born
Bryan C. Hanson	Chief Executive Officer & Director	$4.9M	1967
Heather L. Knight	Chief Commercial Officer	$2.3M	1972
Wayde D. McMillan	Executive VP & CFO	$2.0M	1970
Amy Landucci	Chief Information & Digital Officer	$1.7M	1975
Marcela A. Kirberger	Chief Corporate & Legal Affairs Officer & Corporate Secretary	$1.6M	1967
Tammy L. Gomez	Chief Human Resources Officer	$1.1M	1973
Kate Dobbs	Chief Communications & Corporate Marketing Officer	—	—
Neil C. Zieselman	Senior VP, Controller & Chief Accounting Officer	—	1976

Executive pay, latest proxy

Executive	Year	Salary	Stock awards	Incentive	Total
None on file.

Employees

Dividends

Ex-date	Amount	Paid
None on file.

Moat model

Weak · Cost Advantage · 2026-06-30

Cost advantage67

Intangibles59

Switching costs50

Network effect35

Efficient scale55

Our component scores (0-100) and overall 54.2; a model of the business, not a call on the stock.

InsiderStreet reports findings from filings and market data. Nothing on this page is a recommendation to buy or sell.Every figure is computed in code · data as of 2026-10-17

SOLV

One year, rebased to 100

Score DNA

Flags

Smart-money strip

Key financials · FY2025

Valuation

SOLV vs industry median

Earnings delivery

Peers

Recent 8-K filings

Context

Full factsheet

All fundamentals · 140 measures in 13 categories

Valuation

Profitability (TTM)

Returns on capital

Growth

Margin history & stability

Liquidity (latest quarter)

Leverage & solvency (latest quarter)

Efficiency

Cash flow & earnings quality

Dividends & buybacks

Scores & forensic checks

Per share

Size (TTM)

Insider transactions, last 6 months

Shares acquired vs disposed, by month

By transaction type, 6 months

Form 144 notices

Congress trades

Largest 13F holders

Institutional ownership by quarter

Holder changes by quarter

Schedule 13D / 13G filers

ETFs with the largest holding

Share structure

Income statement

Balance sheet

Cash flow statement

Ratio history

Revenue by region · FY2025

Street estimates by fiscal year

Reported vs expected, every quarter on file

Off-exchange (dark pool) volume, weekly

Short-sale share of off-exchange volume

Seasonality

Indicators

Moving averages and bands

About Solventum Corporation

Key executives

Executive pay, latest proxy

Employees

Dividends

Moat model

Sign in to InsiderStreet